PMC9791028_01
Pelvic MRI on 18 August 2020. The images showed an expansive heterogeneous malignant tumor in the lower abdominal and pelvic cavity (yellow arrows).
fonc-12-1010158-g001.jpg
PMC9791028_01_fonc-12-1010158-g001.jpg
f1
A dynamic magnetic resonance imaging (MRI) scan of the pelvic cavity was performed and revealed an expansive heterogeneous malignant tumor measuring 19.3 cm x 11.1 cm x 10.9 cm in the lower abdominal and pelvic cavity with a large quantity of ascitic fluid, suggesting the possibility of ovarian malignancy ( Figure 1 ).
The gross view of the resected tumor originating from the bilateral ovaries (arrows) and uterus (arrowheads).
fonc-12-1010158-g002.jpg
PMC9791028_01_fonc-12-1010158-g002.jpg
f2
There were cystic-solid tumors with uneven surfaces that originated from the bilateral ovaries with left and right ovaries measuring about 12 and 8 cm in diameter, respectively ( Figure 2 ).
Pelvic MRI on 7 January 2022. A likely metastatic lymph node (yellow arrows) in the anterior area of the left psoas major (red arrow) and left of the common iliac artery was found 15 months after the administration of olaparib.
fonc-12-1010158-g003.jpg
PMC9791028_01_fonc-12-1010158-g003.jpg
f3
On 7 January 2022, 15 months after the administration of olaparib, the latest pelvic MRI scan discovered a nodule (2.5 cm in diameter) with the probability of a metastatic lymph node in the anterior area of the left psoas major and left of the common iliac artery ( Figure 3 ).
The level of alpha fetoprotein (AFP) and cancer antigen 125 (CA125).
fonc-12-1010158-g004.jpg
PMC9791028_01_fonc-12-1010158-g004.jpg
f4
The levels of AFP and CA125 were also slightly elevated (15.90 U/ml and 6.07 ng/ml, respectively, on 7 February 2022) ( Figure 4 ).